Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers

Biopharmaceutics and Drug Disposition

Volumn 27, Issue 6, 2006, Pages 285-289

  Vlase, Laurian ^a   Leucuta, Adrian ^a   Farcau, Dorin ^a   Nanulescu, Mircea ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Drug interaction; Fluoxetine; Metoclopramide; Pharmacokinetics

Indexed keywords

FLUOXETINE; FLUOXIN; METOCLOPRAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; FIRST PASS EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; METHODOLOGY; NORMAL HUMAN; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS; VOLUNTEER;

EID: 33749353523     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.510     Document Type: Article

References (12)

1. Albibi R, McCallum RW. Metoclopramide: pharmacology and clinical application. Ann Intern Med 1983; 98: 86-95.
2. Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC. Metocloprantide. An updated review of its pharmacological properties and clinical use. Drugs 1983; 25: 451-494.
3. Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998; 104: 252-258.
4. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53: 401-409.
5. Desta Z, Wu GM, Morocho AM, Flockhart DA. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos 2002; 30: 336-343.
6. Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994; 26: 201-214.
7. Baumann P, Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol 1995; 10: 15-21.
8. Caley CF. Extrapyramidal reactions, selective serotonin reuptake inhibitors. Ann Pharmacother 1997; 31: 1481-1487.
9. Bergstrom RF, Goldberg MJ, Cerimele BJ, Hatcher BL. Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. Clin Pharmacol Ther 1997; 62: 643-651.
10. Schuirmann DJ. A comparison of the two one-side test procedure and the power approach for assessment of the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-680.
11. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. July 2002. http://www.fda.gov/cder/guidance/4964dft.htm/ [16 March 2005].
12. The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products. Note for Guidance on the Investigation of Bioavailability and Bioequivalence. London, July 2001. http://www. emea.eu.int/pdfs/human/ewp/140198en.pdf [16 March 2005].